A Phase 1, Multi-Center, Open-Label Study To Assess The Safety, Pharmacokinetics, And Preliminary Efficacy Of An Orally Available Small Molecule, CC-99282, Alone And In Combination With Rituximab In Subjects With Relapsed Or Refractory Non-Hodgkin Lymphomas (R/R NHL) Read more
Outcomes Of Patients With Aggressive B-Cell Non-Hodgkin S Lymphoma Who Undergo Hematopoietic Cell Transplantation After CAR T-Cell Therapy Read more
A Phase 2 Study Of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, And Prednisone (CHEP-BV) Followed By BV Consolidation In Patients With CD30-Positive Peripheral T-Cell Lymphomas Read more
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin And Nivolumab Incorporated And Radiation Free Management Of Early Stage Classical Hodgkin Lymphoma (Chl) Read more
A Phase 1/1b Dose-Escalation Trial Evaluating CPI-818, An Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, In Subjects With Relapsed/Refractory T-Cell And Follicular B-Cell Non-Hodgkin Lymphoma Read more
A Phase I Trial Assessing The Feasibility Of Romidepsin Combined With Brentuximab Vedotin For Patients With Requiring Systemic Therapy For Cutaneous T-Cell Lymphoma Read more
A Phase 1/2, Open-Label, Dose-Escalation Trial Of GEN3013 In Patients With Relapsed, Progressive Or Refractory B-Cell Lymphoma Read more
